CD8A and neoplasm: CAR T cell therapy works on the principle that genetically engineered CD8+ T cells expressing TCRs specific for a tumor antigen fused to their native CD3 domain or modified with the endodomain of a costimulatory molecule can become activated and expand into a population of tumor-specific CD8+ cytotoxic T cells (142).